145 related articles for article (PubMed ID: 23857409)
21. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
Lustgarten DE; Deshpande C; Aggarwal C; Wang LC; Saloura V; Vachani A; Wang LP; Litzky L; Feldman M; Creaney J; Nowak AK; Langer C; Inghilleri S; Stella G; Albelda SM
J Thorac Oncol; 2013 Apr; 8(4):469-77. PubMed ID: 23486267
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed therapy for malignant pleural mesothelioma.
Puto K; Garey JS
Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
[TBL] [Abstract][Full Text] [Related]
23. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.
Szlosarek PW; Luong P; Phillips MM; Baccarini M; Stephen E; Szyszko T; Sheaff MT; Avril N
J Clin Oncol; 2013 Mar; 31(7):e111-3. PubMed ID: 23319692
[No Abstract] [Full Text] [Related]
24. The emerging role of pemetrexed for the treatment of malignant mesothelioma.
Kindler HL
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):49-53. PubMed ID: 15339060
[TBL] [Abstract][Full Text] [Related]
25. [Does treatment for malignant pleural mesothelioma exist?].
Riviere A
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S3-6. PubMed ID: 11924240
[No Abstract] [Full Text] [Related]
26. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.
Kao SC; McCaughan B; Muljono A; Boyer M
J Thorac Oncol; 2010 Mar; 5(3):405-6. PubMed ID: 20186029
[No Abstract] [Full Text] [Related]
27. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
Shukuya T; Takahashi T; Nakamura Y; Yamamoto N
Gan To Kagaku Ryoho; 2010 Mar; 37(3):487-90. PubMed ID: 20332689
[TBL] [Abstract][Full Text] [Related]
28. Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.
Ceribelli A; Cecere FL; Milella M; Facciolo F; Gelibter A; Cognetti F
Lancet Oncol; 2006 Apr; 7(4):353. PubMed ID: 16574552
[No Abstract] [Full Text] [Related]
29. [Malignant pleural mesothelioma: further options].
van Hezik EJ
Arch Bronconeumol; 2005 Dec; 41(12):703. PubMed ID: 16373048
[No Abstract] [Full Text] [Related]
30. The new front line treatment for malignant pleural mesothelioma?
Steele JP
Thorax; 2003 Feb; 58(2):96-7. PubMed ID: 12554885
[No Abstract] [Full Text] [Related]
31. Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?
Tamura K; Fujiwara Y
Asia Pac J Clin Oncol; 2010 Dec; 6(4):248-50. PubMed ID: 21114772
[No Abstract] [Full Text] [Related]
32. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
Pistolesi M; Rusthoven J
Chest; 2004 Oct; 126(4):1318-29. PubMed ID: 15486399
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
34. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
Hanauske AR
Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
Zalcman G; Bergot E; Lechapt E
Lung Cancer; 2011 Apr; 72(1):1-2. PubMed ID: 21277041
[No Abstract] [Full Text] [Related]
37. Malignant mesothelioma.
Muñoz A; Barceló R; López-Vivanco G
N Engl J Med; 2006 Jan; 354(3):305-7; author reply 305-7. PubMed ID: 16422026
[No Abstract] [Full Text] [Related]
38. Emerging insights into the biology and therapy of malignant mesothelioma.
Vogelzang NJ
Semin Oncol; 2002 Dec; 29(6 Suppl 18):35-42. PubMed ID: 12571809
[TBL] [Abstract][Full Text] [Related]
39. Complete response and long-term survival in malignant pleural mesothelioma: case report.
Takanen S; Resuli B; Graziano V; Parisi A; Lisi R; Raffetto N; Tombolini V
Anticancer Res; 2012 Apr; 32(4):1485-7. PubMed ID: 22493390
[TBL] [Abstract][Full Text] [Related]
40. Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.
Adusumilli PS
Cancer; 2014 Nov; 120(21):3268-71. PubMed ID: 24989696
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
